Grants for City or township governments - Federal

This funding opportunity provides financial support to small rural hospitals and health clinics to help them improve their healthcare services and transition to a value-based care system for better patient outcomes.

This notice of funding opportuntity (NOFO) encourages applications for investigator-initiated multi site clinical trials (e.g., efficacy, effectiveness, or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions), and/or multicomponent interventions that include physical, psychological, and/or nutritional approaches in NCCIH- designated areas of high research priority. Clinical Coordinating Centers (CCC) should develop and implement the proposed fully powered multi-site clinical trial (Phase III and beyond). The objective of a CCC application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. CCCapplications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific conduct, and dissemination of results. CCC applications submitted under this NOFO will utilize a two-phase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center (DCC) application (U24), submitted under PAR-24-087 proposing a data analysis and data management plan for the clinical project is required. Both a CCC application and a corresponding DCC application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO.

This funding opportunity provides financial support to early-career researchers in the fields of arthritis, musculoskeletal, and skin diseases, helping them conduct small-scale studies as they transition to independent investigator roles.

This program provides funding to U.S. agricultural organizations and businesses to help them develop and expand export markets for American agricultural products in emerging markets.

With this solicitation, OJJDP seeks to support targeted efforts to address youth violence in a school-based setting (K12th grade only). OJJDP seeks to increase school safety through the development and expansion of evidence-based and promising violence prevention and reduction programs and strategies to support school climate. Through this initiative, OJJDP expects applicants to utilize a collaborative approach between schools and community-based organizations (CBOs) to develop and implement these strategies.

The "Addressing the Impact of Structural Racism and Discrimination on Minority Health and Health Disparities" grant aims to fund research projects that explore and address the effects of structural racism and discrimination on the health of minority and disadvantaged groups, with the goal of improving health outcomes and promoting health equity.

Fort Wainwright Alaska and Donnelly Training Area Land Rehabilitation and Maintenance Support, Fort Wainwright, Alaska - The primary objective of this requirement is to implement the Integrated Natural Resources Management Plan (INRMP) to provide healthy and resilient environments that are sustainable, high-quality settings for military training and to protect and enhance biological diversity and ecological health on all Department of Defense (DoD) lands, and to ensure compliance with all environmental laws and regulations. See full Funding Opportunity Description in Section I.

This funding opportunity provides financial support to early-career researchers in the dental and craniofacial fields to conduct pilot studies that will help them secure larger research grants in the future.

(Reissue of PAR-18-486) The purpose of the NINDS Faculty Development Award to Promote Diversity in Neuroscience Research (K01) is to diversify the pool of independent neuroscience research investigators by providing junior faculty with research cost support, protected research time and career stage appropriate professional development mentorship in neuroscience research. Individuals from backgrounds underrepresented in biomedical research are eligible for support under this award if they have doctoral research degrees (Ph.D. or equivalent) and are in the first 3 years of a faculty tenure track or equivalent position at the time of application. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. NINDS will only accept applications to this FOA that propose human mechanistic trials/studies that meet NIH's definition of a clinical trial and that fall within the NINDS research priorities. Applicants are strongly advised to consult with NINDS program staff prior to submitting an application with human subjects to determine the appropriate funding opportunity.

This funding opportunity supports U.S.-based nonprofit organizations, academic institutions, and government agencies in enhancing public access to historical records through preservation, digitization, and improved discoverability of archival collections.

The purpose of this Notice of Funding Opportunity Announcement (NOFO) is to solicit applications for the Coordinating Center (CC) of the ML/AI Tools to Advance Genomic Translational Research (MAGen) Consortium. In collaboration with the MAGen Sites funded by the companion NOFO (RFA-HG-24-004) the CC will explore the feasibility of developing Machine Learning (ML) and Artificial Intelligence (AI) tools that can enhance the accuracy and precision of predicting how individuals with pathogenic genetic variants manifest disease. The CC will be responsible for implementing approaches to bring diverse teams together to enable synergistic and collaborative team science across the Consortium. Specifically, the CC will be responsible for technical, scientific, and administrative coordination activities to support the Consortium research activities including development of consortium wide plans, coordinated ELSI-informed ML/AI tool development and cross validation, and dissemination of the developed resources.

Substance use needs to be better incorporated into interventions for the engagement and retention of sexual minority persons in prevention and care with attention to emergent interventions such as long-acting PrEP. Social determinants of health associated with HIV and problematic substance use such as homelessness and criminal justice involvement also demonstrate disproportionate impact among sexual and gender minorities and need attention. Changing self-definition of sexual minority status has implications for outreach and provider stigma and needs to be better integrated into interventions. This initiative will address these gap areas and support epidemiologic, intervention, and implementation research that incorporates attention to HIV as a syndemic including comorbidities such as STIs, HCV, and psychiatric disorder.

This funding opportunity supports researchers in analyzing and integrating existing data to better understand cancer risks and outcomes, ultimately advancing cancer research and treatment strategies.

This funding opportunity provides financial support to water and power authorities, as well as nonprofit conservation organizations in the western U.S., to implement projects that enhance water efficiency, promote renewable energy, and improve sustainability in response to water scarcity and climate challenges.

The United States Department of the Interior (Department), Bureau of Reclamations (Reclamation) Desalination and Water Purification Research Program (DWPR) works with Reclamation researchers and partners to develop innovative, cost-effective, and technologically efficient ways to desalinate and treat water. DWPR funding plays a critical role in iterating an idea from the lab to a real-world demonstration, yielding products that serve the water treatment community and attract commercialization interest. Reclamation is interested in research where the benefits are widespread but where private-sector entities are not able to make the full investment and assume all the risks. Reclamation is also interested in research that has a national significancewhere the issues are of large-scale concern and the benefits accrue to a large sector of the public. The goal of the DWPR program is to address the need to reduce the costs, energy requirements, and environmental impacts of treating impaired and unusable water. The program also aligns with Executive Order 14008, Tackling the Climate Crisis at Home and Abroad, by investing in development and application of advanced water treatment technologies that expand access to otherwise unusable water resources, thereby increasing water supply flexibility under the risks of long-term climate change and shorter-term drought. For further information on the DWPR Program, see www.usbr.gov/research/dwpr.

This grant provides funding for a Data Coordinating Center to support research projects focused on preventing stillbirth, emphasizing collaboration and equity in addressing disparities in vulnerable populations.

The "Research on Autism Spectrum Disorders" grant aims to fund projects that explore the causes, prevalence, diagnosis, and best service delivery methods for Autism Spectrum Disorders, with a focus on small, well-defined projects that can be completed within two years using limited resources.

The National Institutes of Health (NIH) hereby notify recipient organizations holding specific types of NIH grants, listed in the full Funding Opportunity Announcement (FOA), that applications for change of recipient organization may be submitted to this FOA. This assumes such a change is programmatically permitted for the particular grant. Applications for change of recipient organization are considered prior approval requests (as described in Section 8.1.2.7 of the NIH Grants Policy Statement) and will be routed for consideration directly to the Grants Management Specialist named in the current award. Although requests for change of recipient organization may be submitted through this FOA, there is no guarantee that an award will be transferred to the new organization. All applicants are encouraged to discuss potential requests with the awarding IC before submission.

The purpose of this Notice of Funding Opportunity (NOFO) is to support the development of clinical research platforms that will enable future clinical trials to determine whether combinations of HIV cure strategies can be effective when optimally tailored to the participants. The ultimate goal is for the results of such proof-of-concept clinical studies to inform the development and prioritization of more broad-based curative strategies that will be effective in all people living with HIV. This NOFO will support multidisciplinary teams to conduct coordinated basic and pre-clinical research to profile participants intact, rebound-competent HIV reservoirs and immunologic backgrounds and use that information to develop and test combinations of HIV curative approaches that are specifically tailored to those participants.

Modified release (MR) oral drug products are considered to have a high risk for alcohol dose dumping (ADD) because they contain large quantities of drug(s), designed to release over a prolonged period of time. Accidental exposure of these products to alcohol can result in the relatively rapid release of large quantities of drug with severe side effects, including death. To mitigate this risk, the FDA recommends conducting an in vitro alcohol dose dumping assessment in 0%, 5%, 20%, and 40% alcoholic dissolution media for all prospective generic versions of MR oral drug products. To date, ADD assessments have not been harmonized globally. For instance, the U.S. FDA recommends testing up to 40% alcoholic media while the European Medicines Agency recommends testing up to 20% alcoholic media. This type of difference can present a challenge for formulators designing products for multiple markets, as historical data has shown release from MR oral products do not always follow a linear response (either increasing or decreasing) to increasing alcohol concentrations. In addition, interpretation of an ADD assessment may be limited by the inability of the test to predict in vivo behavior. The purpose of this research is to develop tools that 1) facilitate the development of MR generic drug products that have a low potential for ADD, 2) support regulatory decision making during the assessment of such products, and 3) provide evidence that enables FDA to develop more specific recommendations for efficiently demonstrating a low or comparative potential of alcohol dose dumping for MR oral drug products containing high risk drugs.